For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Medsafe warns consumers not to consume coffee product marketed for weight loss
Medsafe warns consumers not to consume coffee product marketed for weight loss

Medsafe has today published a privileged statement issued by the Director-General of Health under section 98 of the Medicines Act 1981.
This statement is issued as an alert to warn consumers of the dangers of consuming a product marketed for weight loss, under the branding Valentus SlimROAST Optimum Dark Roast Coffee (sachets and powder). The product has been tested by Medsafe and found to contain the prescription medicine methylhexanamine (DMAA), and also phenethylamine, a controlled drug.
The warning is published at the following link: https://www.medsafe.govt.nz/safety/Alerts/ValentusSlimRoast.asp
Consumers should not consume the product and should return it to the supplier or dispose of it safely.
Valentus SlimROAST Optimum Dark Roast Coffee has been sold for weight loss / management and is claimed to improve mood and focus, regulate blood sugar and boost circulation.
There’s no reliable information about how many people have taken the product.
Medsafe has seized the stock of one supplier however there are expected to be other suppliers importing and distributing the product.
Consumers should seek medical advice if they feel unwell when taking the product.
Adverse reactions to the product should be reported to the Centre for Adverse Reactions Monitoring: https://nzphvc.otago.ac.nz/report/.
Consumers can also report any concerns to Medsafe: www.medsafe.govt.nz/safety/report-a-problem.asp.
This warning has been issued as a privileged statement by the Director-General of Health under section 98 of the Medicines Act 1981.